Traversa Therapeutics
Traversa Therapeutics: Advancing RNAi delivery technologies for acute, chronic, and infectious diseases treatment.
Founded
2006Traversa Therapeutics: Advancing RNAi delivery technologies for acute, chronic, and infectious diseases treatment.
Founded with the mission to revolutionize RNA interference (RNAi) therapies, Traversa Therapeutics is a biopharmaceutical company dedicated to the discovery, development, and commercialization of RNAi delivery technologies. The company's core focus is on optimizing short interfering RNA (siRNA) platform delivery technologies, aiming to provide effective solutions for a wide array of acute, chronic, and infectious human diseases. Traversa Therapeutics not only enhances delivery mechanisms for RNAi therapeutic companies but also advances its own therapeutic programs.
Traversa Therapeutics has garnered attention from notable figures in the biopharmaceutical industry and has attracted significant investment to support its innovative research. The company's achievements include the development of cutting-edge siRNA delivery platforms that have the potential to transform disease treatment paradigms. Through its pioneering work, Traversa Therapeutics is making a substantial impact on the field of RNAi therapeutics, offering promising new avenues for treating complex medical conditions.
Companies similar to Traversa Therapeutics include Silence Therapeutics, Quark Pharmaceuticals, Alltrna and Switch Therapeutics.
Traversa Therapeutics was founded in 2006.
Traversa Therapeutics' headquarters is located in San Diego, CA, US.
Traversa Therapeutics' most recent funding round was for $5M (USD) in April 2009.
As of Apr 7, 2009, Traversa Therapeutics has disclosed funding of $7M (USD). Undisclosed round amounts are excluded.
Traversa Therapeutics has 30 employees as of Feb 4, 2024.
Switch Therapeutics
switchthera.com
